115 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.
Merck Research Laboratories
OpenGrowth: An Automated and Rational Algorithm for Finding New Protein Ligands.
Harvard University
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
Shandong University
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Philipps-Universit£T Marburg
Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
Peking Union Medical College
An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.
University of Michigan
Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors.
University of Florence
Impact of Stereochemistry on Ligand Binding: X-ray Crystallographic Analysis of an Epoxide-Based HIV Protease Inhibitor.
University of Trieste
Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
Kyoto Pharmaceutical University
Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
University of Massachusetts Medical School
Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation.
Purdue University
Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
Purdue University
Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir.
TBA
Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.
Purdue University
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
Purdue University
Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
Peking Union Medical College
Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands.
Peking Union Medical College
Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants.
Peking Union Medical College
HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
University of Massachusetts Medical School
Synthetic, structural mimetics of the β-hairpin flap of HIV-1 protease inhibit enzyme function.
University of Maryland
Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
Purdue University
Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods.
Nankai University
Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
Purdue University
Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
Purdue University
Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Georgia State University
Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
Shandong University
Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor.
Kyoto Prefectural University of Medicine
Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
Universidad De Granada
Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease.
University of Lyon
Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
Wayne State University
Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.
Uppsala University
Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.
Purdue University
Dissecting the pharmacophore of curcumin. Which structural element is critical for which action?
University of Eastern Piedmont
Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors.
Rhodes University
Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease.
Georgia State University
Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold.
Academy of Sciences of The Czech Republic
Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization.
Paris-Sud University
Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.
Sanford-Burnham Medical Research Institute
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
Universidad De Santiago De Compostela
Synthesis and biological activity of potent HIV-1 protease inhibitors based on Phe-Pro dihydroxyethylene isosteres.
University of Trieste
Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.
Georgia State University
Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors.
University of Southampton
Synthesis and molecular modelling studies of novel carbapeptide analogs for inhibition of HIV-1 protease.
University of Kwazulu-Natal
Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors.
Uppsala University
Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety.
University of Basilicata
Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.
Purdue University
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
Chinese Academy of Sciences
Design, synthesis, and X-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors.
Stevens Institute of Technology
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.
Purdue University
Novel 3alpha-methoxyserrat-14-en-21beta-ol (PJ-1) and 3beta-methoxyserrat-14-en-21beta-ol (PJ-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as HIV agents.
Osaka University of Pharmaceutical Sciences
Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.
University of Kwazulu-Natal
Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.
Kyoto Pharmaceutical University
Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors.
Kyoto Pharmaceutical University
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
Purdue University
Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.
University of Massachusetts Medical School
Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
Jadavpur University
Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
Beijing Institute of Biotechnology
Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors.
Merck Research Laboratories
Inhibition of the dimerization and active site of HIV-1 protease by secondary metabolites from the Vietnamese mushroom Ganoderma colossum.
University of Toyama
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.
Purdue University
Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
University of Minnesota
Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases.
University of Basilicata
3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
Universidade Federal De Lavras
Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates.
Uppsala University
HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Uppsala University
Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
Kyoto Pharmaceutical University
Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
Stockholm University
Evaluation of triazolamers as active site inhibitors of HIV-1 protease.
New York University
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
National Cancer Institute
On the inhibition of HIV-1 protease by hydrazino-ureas displaying the N-->C=O interaction.
University of Lyon
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Glaxosmithkline
Synthesis of dammarane-type triterpene derivatives and their ability to inhibit HIV and HCV proteases.
University of Toyama
A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant.
The Scripps Research Institute
Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
Georgia State University
Anti-HIV-1 activity of phloroglucinol derivative, 6,6'-bieckol, from Ecklonia cava.
Pukyong National University
Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
University of Minnesota
Anti-HIV-1 protease activity of lanostane triterpenes from the vietnamese mushroom Ganoderma colossum.
University of Toyama
Microbial transformation of L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease.
Merck Research Laboratories
In silico screening of HIV-1 non-nucleoside reverse transcriptase and protease inhibitors.
Universidade Federal De Minas Gerais
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Academy of Sciences of The Czech Republic
Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.
Kyoto Pharmaceutical University
Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbifolia.
Toyama Medical and Pharmaceutical University
Guaiane dimers and germacranolide from Artemisia caruifolia.
Toyama Medical and Pharmaceutical University
Anti-HIV-1 protease triterpenoid saponins from the seeds of Aesculus chinensis.
Beijing Medical University
Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
Kyoto Pharmaceutical University
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
Kumamoto University Graduate School of Medical and Pharmaceutical Sciences
Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
Philipps-Universit£T Marburg
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
Dainippon Sumitomo Pharma
Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.
Uppsala University
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Purdue University
Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
Merck Research Laboratories
Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality.
University of Minnesota
Brominated polyacetylenic acids from the marine sponge Xestospongia muta: inhibitors of HIV protease.
Smithkline Beecham Pharmaceuticals
Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.
Georgia State University
Isolation and synthesis of a new bioactive ellagic acid derivative from Combretum yunnanensis.
Teikyo University
Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.
Purdue University
Druggability Assessment of Targets Used in Kinetic Target-Guided Synthesis.
University of Groningen
Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
Purdue University
Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir.
TBA
Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.
Kobe Gakuin University
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.
Merck
Design and synthesis of selenazole-substituted ritonavir analogs.
Chinese Academy of Science
Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2-ligand: Structure-activity studies and biological evaluation.
Peking Union Medical College
